Risk factors for hepatotoxicity in patients hospitalized for tuberculosis

Creative Commons License

ERGAN B., Kirmizigul E., UZUN Ö., ÇÖPLÜ L.

EUROPEAN JOURNAL OF GENERAL MEDICINE, cilt.14, sa.1, ss.1-4, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.29333/ejgm/81870
  • Dergi Adı: EUROPEAN JOURNAL OF GENERAL MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Academic Search Premier, CINAHL
  • Sayfa Sayıları: ss.1-4
  • Anahtar Kelimeler: tuberculosis, drug, side effect, ANTITUBERCULOSIS DRUGS, LIVER-INJURY, RHEUMATOID-ARTHRITIS, LATENT TUBERCULOSIS, ISONIAZID TREATMENT, THERAPY, METHOTREXATE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Introduction: Combination therapy with four drugs (isoniazid, rifampicin, pyrazinamid and ethambutol) is the treatment of choice in tuberculosis but hepatotoxicity due to these drugs is an important medical concern. Therefore identification of patient groups with increased risk for antituberculosis therapy induced hepatotoxicity is crucial.